

Medication:	Ofatumumab - Kesimpta
Med Class:	Monoclonal Antibody
Common Uses:	Treatment for relapsing multiple sclerosis including clinically isolated syndrome (CIS) and active secondary progressive disease.
Route(s):	SC

Instructions/Precautions:	<ul style="list-style-type: none"> • Ages: 18 and up. Pediatric safety and effectiveness has not been established. Clinical studies did not include enough geriatric patients to determine if there is a difference in response from younger patients. • Recommended Dosage: Initial dosing of 20 mg by subcutaneous injection at Weeks 0, 1, and 2, followed by subsequent dosing of 20 mg by subcutaneous injection once monthly starting at Week 3. • Instructions: Missed doses should be administered as soon as possible. Should only be administered subcutaneously. Pens and syringes are single-use only. • Precautions: Any live-attenuated or live vaccines should be administered 4 weeks prior to initiation and not recommended to give during treatment and not until B-cell repletion post treatment. Potential drug interactions with immunosuppressive or immune modulating therapies. May cause Progressive Multifocal Leukoencephalopathy (PML). PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. Stop the medication immediately and report the following to MD: new or worsening neurologic signs or symptoms including weakness on one side of the body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes. • Side effects: Increased risk for infections, including serious bacterial, fungal, and viral infections. Most common infections: respiratory, and UTI. Local injection reactions. Reduction in Immunoglobulins. Headaches. • Contraindications: Active HBV infection confirmed by positive antigen/anti-HBV screening results. Delay administration until active infections resolve. Pregnancy. • Prior to First Dose: First dose should only be administered under the guidance of a home health care RN. Assess if active HBV, confirmed by positive antigen/anti-HBV screening results. Positive for HBV core antibody or HBV carriers, but negative for HBsAg – consult liver disease experts before starting or during treatment. Follow HHVNA first dose/anaphylaxis policy and procedure - ensure nurse has anaphylaxis kit present.
---------------------------	--

First Dose Allowed:	Yes
---------------------	-----

Special Training Required:

Sources:

1. Fda.gov. (8/2020). Kesimpta Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf
2. Kesimpta.com. (2021). What is Kesimpta? Retrieved from <https://www.kesimpta.com/about-kesimpta/what-is-kesimpta/>

Note: Nurse will not administer medication if special training is required and nurse has not received training; Contact your Clinical Manager immediately